MedPath

Exploratory Study of the Relationships Between the Biomarkers of Inflammation, Lipidome and Insulin Resistance and Disorders of Glycemic Regulation in a Cohort of Insulin-resistant Subjects Due to Excess Weight or Dunnigan's Lipodystrophy

Not Applicable
Completed
Conditions
Lipodystrophy
Dunnigan Syndrome
Interventions
Other: research-specific blood sample
Registration Number
NCT05424913
Lead Sponsor
Centre Hospitalier Universitaire de la Réunion
Brief Summary

The objective of this work is to identify biomarkers of interest in patients with insulin resistance leading to early disorders of glycemic regulation. For this the investigators want to assay the insulin resistance marker Insulin Regulated Amino Peptidase serique (IRAPs), the plasma lipidome and inflammation markers in 2 populations of insulin-resistant subjects due to Dunnigan's inherited lipodystrophy or overweight/obesity and insulin-sensitive subjects with or without a glycemic regulation disorder objectified during an Oral induced hyperglycemia. The results of the IRAPs, lipidome and inflammation assays will be compared in insulin-resistant subjects, between normoglycemic, prediabetic and diabetic subjects. Correlations will be made between these markers and the deterioration of glycemic regulation as well as with known insulin resistance parameters (HOmeostasis Assessment Model (HOMA), Quantitative Insulin-sensitivity Check Index (QUICKI),Insulin Sensitivity Index (Isi) MATSUDA).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
150
Inclusion Criteria
  • Subjects with Dunnigan's Lipodystrophy OR Non-lipodystrophic insulin-resistant subjects OR Insulin-sensitive non-lipodystrophic subjects
  • major
  • Subjects benefiting from metabolic exploration in the Endocrinology, Diabetology and Nutrition department of the Reunion University Hospital.
  • Subject benefiting from an oral glucose tolerance test (OGTT) during his follow-up in the Endocrinology, Diabetology and Nutrition department of the Reunion University Hospital.
  • Person affiliated or beneficiary of a social security scheme.
  • Subject having been informed of the study in progress and having given their written consent.
Exclusion Criteria
  • Pregnant woman
  • Person under guardianship or curators or deprived of liberty

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Insulin-sensitive non-lipodystrophic subjectsresearch-specific blood sample-
Subjects with Dunnigan's Lipodystrophyresearch-specific blood sample-
Non-lipodystrophic insulin-resistant subjectsresearch-specific blood sample-
Primary Outcome Measures
NameTimeMethod
Insulin Regulated Amino Peptidase sérique (IRAPs) levelsat inclusion

Insulin Regulated Amino Peptidase sérique (IRAPs)

inflammation markers levelsat inclusion

TNF-α (tumor necrosis factors-α), IL-1β (interleukin-1β), IL-2, IL-6, IL-18, IFN-γ (interferon-γ) et MCP-1 (monocyte chemoattractant protein-1), IL-10, IL-4, IL-5

lipidome markers levelsat inclusion

662 plasma lipid species

Secondary Outcome Measures
NameTimeMethod
Compare levels of inflammation markers between the 3 categories of participantsat inclusion

TNF-α (tumor necrosis factors-α), IL-1β (interleukin-1β), IL-2, IL-6, IL-18, IFN-γ (interferon-γ) et MCP-1 (monocyte chemoattractant protein-1), IL-10, IL-4, IL-5

Compare levels of lipidome markers between the 3 categories of participantsat inclusion

662 plasma lipid species

Compare levels of Insulin Regulated Amino Peptidase sérique (IRAPs) between the 3 categories of participantsat inclusion

Insulin Regulated Amino Peptidase sérique (IRAPs)

Trial Locations

Locations (1)

CHU de la Réunion

🇷🇪

Saint-Pierre, Réunion

© Copyright 2025. All Rights Reserved by MedPath